This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Johns Hopkins University. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Shonoi Ming: Innovator in Cancer and Neurodegenerative Disease Research
Introduction
Shonoi Ming is a prominent inventor based in Baltimore, MD (US). He has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic agents targeting specific enzymes involved in cancer and neurodegenerative diseases.
Latest Patents
Ming holds a patent for "Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)." This patent describes a series of phenelzine analogs that comprise a phenelzine scaffold linked to an aromatic moiety. These compounds serve as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs). The disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes. They also demonstrate significant changes in histone methylation, anti-proliferative activity in various cancer cell lines, and neuroprotection against oxidative stress. Consequently, these analogs have potential applications in treating diseases related to LSD1 and/or HDACs, including cancers and neurodegenerative disorders.
Career Highlights
Shonoi Ming is affiliated with Johns Hopkins University, where he conducts his research. His work has garnered attention for its innovative approach to addressing complex medical challenges. With a focus on enzyme inhibitors, Ming's research aims to provide new avenues for therapeutic intervention in serious health conditions.
Collaborations
Ming collaborates with notable researchers in his field, including Philip A. Cole and Polina Prusevich. These collaborations enhance the depth and impact of his research, fostering advancements in understanding and treating diseases.
Conclusion
Shonoi Ming is a key figure in the development of innovative treatments for cancer and neurodegenerative diseases. His patented work on phenelzine analogs represents a significant advancement in the field of biomedical research.